Table 2 Clinical data and tryptase values of patients with NSAID hypersensitivity as well as the hymenoptera venom allergy group
NSAID | Comparison group: hymenoptera venom allergy | P values | |
|---|---|---|---|
Number of patients | 284 | 484 | n.a. |
Mean age (range) | 51 (10–89) | 47 (7–81) | .026 |
Male/female | 81/203 | 287/197 | < .001 |
Severity of anaphylaxis | < .001 | ||
Grade 1 | 174 (61.3%) | 26 (5.4%) | |
Grade 2 | 110 (38.7%) | 249 (51.4%) | |
Grade 3 | 0 (0.0%) | 209 (43.2%) | |
Application | n.a. | ||
Oral | 249 | n.a. | |
Intravenous | 14 | n.a. | |
Intramuscular | 19 | n.a. | |
Suppository | 2 | n.a. | |
Basal serum tryptase | .004 | ||
Minimum [ng/mL] | 0.0 | 0.0 | |
Maximum [ng/mL] | 94.8 | 148.0 | |
Mean [ng/mL] | 5.9 | 7.8 | |
0.0 to 5.0 ng/mL | 166 (58.5%) | 276 (57.0%) | |
> 5.0 to 10.0 ng/mL | 92 (32.4%) | 125 (25.8%) | |
> 10.0 ng/mL | 26 (9.2%) | 83 (17.1%) | |
> 10.0 to 20.0 ng/mL | 20 (7.0%) | 54 (11.2%) | |
> 20.0 to 50.0 ng/mL | 5 (1.8%) | 24 (5.0%) | |
> 50.0 ng/mL | 1 (0.4%) | 5 (1.0%) |